Dr. Reddy’s, Prestige BioPharma ink pact on cancer drug
The Hindu
DRL gets rights to commercialise proposed trastuzumab biosimilar in select LatAm, S-E Asia markets.
Pharma major Dr. Reddy’s Laboratories has entered into a partnership with Prestige BioPharma under which it will get exclusive rights to supply and commercialise the Singapore firm’s proposed trastuzumab biosimilar in select Latin America and Southeast Asian countries.
Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin. It can be prescribed for treatment of HER2 positive breast and metastatic gastric cancer, the two companies said in a release on a binding agreement they have signed.
According to BACL, the biophilic-inspired business park will offer smart workspaces within a vibrant public realm. The project’s most exceptional and breathtaking attribute lies in the Urban Forest, a lush oasis in the centre of the development. This green space will serve as a focal point, seamlessly blending indoor and outdoor spaces throughout the area. The upcoming metro station in Airport City will provide seamless connectivity to the business park from the northern side, ensuring convenient accessibility.